IP waiver will not boost vaccine production: OPPI
The Hindu
‘Critical know-how key to scaling up’
The Organisation of Pharmaceutical Producers of India (OPPI) on Monday said waiving intellectual property rights will not lead to increased production of COVID-19 vaccines, as it is not the barrier to their adequate availability in India. A proposal moved by India and South Africa before the World Trade Organisation (WTO) to temporarily suspend trade-related aspects of intellectual property rights for the COVID-19 vaccines to increase their access amid the pandemic has gained support across a number of countries, including the U.S. Vaccine manufacturing is a complex process and scaling up capacities involves the transfer of critical know-how, it added.More Related News













